Persönliche Daten

Kontakt

Beruflicher und wissenschaftlicher Werdegang

Mitgliedschaften   

Publikationen

Originalarbeiten

Klass DM, Bührmann K, Sauter G, Del Puppo M, Scheibner J, Fuchs M, Stange EF. Biliary lipids, cholesterol and bile synthesis: different adaptive mechanisms to dietary cholesterol in lean and obese subjects. Aliment Pharmacol Ther. 2006; 23: 895-905

Klass DM, Lauer N, Hay B, Kratzer W, Fuchs M and the EMIL Study Group. Arg64 variant of the ß3-adrenergic receptor is associated with gallstone formation. Am J Gastroenterol 2007; 102: 2482-7

Renner O, Harsch S, Schaeffeler E, Schwab M, Klass DM, Kratzer W, Stange EF. Mutation screening of apical sodium-dependent bile acid transporter (SLC10A2): novel haplotype block including six newly identified variants linked to reduced expression. Hum Genet 2009; 125: 381-91.

Walcher T, Haenle MM, Kron M, Hay B, Mason RA, Walcher D, Steinbach G, Kern P, Piechotowski I, Adler G, Boehm BO, Koenig W, Kratzer W, EMIL Study Group. Vitamin C supplement use may protect against gallstones: an observational study on a randomly selected population. BMC Gastroenterol 2009; 9: 74.

von Schmiesing A, Schmidt SA, Kratzer W, Mason RA, Imhof A, Steinbach G, Akinli AS, Haenle MM, EMIL Study Group. Determination of reference values for the soluble transferrin receptor (sTfR) on a cross sectional population sample. Clin Lab 2009; 55: 193-9.

Walcher T, Haenle MM, Mason RA, Koenig W, Imhof A, Kratzer W, EMIL Study Group. The effect of alcohol, tobacco and caffeine consumption and vegetarian diet on gallstone prevalence. Eur J Gastroenterol Hepatol 2010; 22: 1345-51.

Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP, SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-206.

Poster

Klass DM, Ball G, Zimmermann J, Kallien G, Fuchs M, Stange EF, Scheibner J. Gallstone carriers lack feedback regulation of cholesterol metabolism without biliary hypersecretion. Gastroenterology 2000; 118: A972.

Ball G, Klass DM, Zimmermann J, Fuchs M, Stange EF, Scheibner J. Ein fehlender negativer Feedback der Cholesterinsynthese ist ohne Bedeutung für die biliäre Cholesterinsekretion beim Gallensteinträger. Aktuelle Ernährungsmedizin 2000; 25, 84-114. (oral presentation)

Klass DM, Bührmann K, Sauter G, Del Puppo M, Stange EF, Fuchs M, Scheibner J. Stable biliary cholesterol saturation despite a high cholesterol diet is achieved by different mechanisms in lean and obese subjects. Hepatology 2001; 34: 354A. (oral presentation)

Bührmann K, Klass DM, Zimmermann J, Fuchs M, Stange EF, Scheibner J. Gallenstein-Patienten reagieren auf die Cholesteringabe nicht mit einer Erhöhung der biliären Desoxycholinsäure. Z.Gastroenterol 2001; 39: 672.

Klass DM, Seneshaw M, Kratzer W, Adler G, Fuchs M and the EMIL Study Group. ADRB3 Trp64Arg and GNB3 C825T polymorphisms are genetic markers frequently observed in gallstone carriers. J Hepatology 2004; 40, Supp. 1: 92.

Deckert M, Klass DM, Hänle M, Steinbach G, Kratzer W, Adler G, Fuchs M and the  EMIL Study Group. Prävalenz pathologischer Leberwerte und assoziierter Risikofaktoren in Südwestdeutschland. Z Gastroenterol 2004; 42: P280.

Klass DM, Konikoff F, Gilat T, Adler G, Leikin-Frenkel A, Fuchs M. Fatty acid bile acid conjugates (FABACS) verhindern die Entstehung einer Fettleber durch eine Änderung der Expression hepatischer Lipidtransporter. Z Gastroenterol 2004; 42: P281.

Villagrasa M, Klass DM, Holzmann KH, Adler G, Fuchs M. Differentially expressed genes in mouse liver during development of fatty liver disease (FLD). Z Gastroenterol 2004; 42: P282.

Seneshaw M, Klass DM, Adler G, Davidson NO, Fuchs M. Hepatobiliary lipid metabolism is impaired in Liver Fatty Acid Binding Protein 1 (FABP1) deficient mice. Hepatology 2004; 40: 492A.

Seneshaw M, Klass DM, Preiss E, Adler G, Davidson NO, Fuchs M. Liver Fatty Acid Binding Protein 1 (FABP1) plays a critical role in bile acid and cholesterol metabolism in mice. J Hepatology 2005; 42, Supp. 2: 24. (oral presentation)

Seneshaw M, Klass DM, Elizabeth N, Preiss E, Seedorf U, Adler G, Davidson NO, Fuchs M. Compensatory hepatic up-regulation of bile acid synthesis in liver fatty acid binding protein (Fabp1) knockout mice provides novel insights into the physiological role of FABP1. Gastroentrology 2006; 130: A376. (oral presentation)

Klass DM, Klaus J, Gülsahin O, Hartmann C, Adler G, Fuchs M. Antiviral therapy with peginterferon alfa-2a and ribavirin non-permanently increases bone mineral density in patients with chronic viral hepatitis C. Hepatology 2009; 50: 926A.

Klass DM, Hänle M, Hütter M-L, Adler G, Kratzer W und die EMIL und Römerstein Study Group. Virale Hepatitis-Infektion in der allgemeinen Bevölkerung: Eine bevölkerungsbasierte Studie im Süden Deutschlands. Z Gastroenterol 2010; 48: P596.

Klass DM, Zizer E, Link R, Heyne R, Lutz T, Schmidt W, Goesseringer R, Alshuth U, Mauss S, Hueppe D. The role of ferritin as a response marker for antiviral treatment of chronic Hepatitis C patients with PegInterferon alfa-2a (PegIFN) and Ribavirin (RBV). Hepatology 2011; 54: 868A

Schuchmann M, Kittner JM, Schlaak JF, Klass DM, Eisenbach C, Berg T, Trautwein C, Günther R, Zeuzem S, Gösseringer R, Ehrlich A, Neumann K, Wachtlin D, Boecher WO, Galle PR. Safety, tolerability and Hepatitis C kinetics during treatment with all-trans retinoic plus pegylated Interferon and Ribavirin in Patients with previous non-response – Results of the atraction study. Hepatology 2011; 54: 1001A